Royal Marsden NHS Foundation Trust

Running trials

• Not yet recruiting

  Prostate Cancer in UK Prisons: A Retrospective Data Analysis

  NCT07870707· Royal Marsden NHS Foundation Trust· Source

• Recruiting

  Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT07665515· Phase 1· Epitopea Ltd· Source

• Recruiting

  Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer

  NCT07751133· Phase 3· University College, London· Source

• Recruiting

  Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC

  NCT07718243· Phase 1/2· Institute of Cancer Research, United Kingdom· Source

• Recruiting

  A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

  NCT07393282· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies

  NCT07613723· Phase 1· Zelluna Immunotherapy AS· Source

• Recruiting

  A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  NCT07226843· Phase 1· Eli Lilly and Company· Source

• Recruiting

  A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

  NCT07549321· Phase 2/3· Renaissance Pharma Ltd.· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Incyte Corporation· Source

• Recruiting

  Feasibility of Serial Multisite Image-guided Biopsy to Study Breast Cancer Evolution

  NCT07084571· Royal Marsden NHS Foundation Trust· Source

• Recruiting

  A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07284758· Phase 2· C4 Therapeutics, Inc.· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· CellCentric Ltd.· Source

• Recruiting

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  NCT07221500· Phase 2· Nurix Therapeutics, Inc.· Source

• Recruiting

  Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery

  NCT07159711· Guy's and St Thomas' NHS Foundation Trust· Source

• Enrolling by invitation

  CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma

  NCT06605833· Royal Marsden NHS Foundation Trust· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Recruiting

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· Phase 2/3· Exelixis· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Nuvalent Inc.· Source

• Recruiting

  Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer

  NCT07008742· Royal Marsden NHS Foundation Trust· Source

• Recruiting

  Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients

  NCT07673861· Royal Marsden NHS Foundation Trust· Source

• Recruiting

  A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

  NCT06522737· Phase 3· SecuraBio· Source

• Recruiting

  Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

  NCT07002320· Phase 1/2· Institute of Cancer Research, United Kingdom· Source

• Recruiting

  A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

  NCT06843447· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Preoperative Planning With PSMA-PET in Melanoma Surgery Trial

  NCT06560905· Phase 2· Royal Marsden NHS Foundation Trust· Source

• Active, not recruiting

  Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

  NCT06840483· Phase 2· BicycleTx Limited· Source

• Active, not recruiting

  Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

  NCT06727565· Phase 2· Gilead Sciences· Source

• Recruiting

  Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions

  NCT06638541· Royal Marsden NHS Foundation Trust· Source

• Recruiting

  SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

  NCT06743126· Phase 3· Immatics US, Inc.· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Pfizer· Source

• Recruiting

  A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

  NCT06581406· Phase 2/3· Replimune, Inc.· Source

• Recruiting

  Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  NCT06472245· Phase 3· OSE Immunotherapeutics· Source

• Active, not recruiting

  Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

  NCT06506955· Phase 2/3· Taiho Oncology, Inc.· Source

• Active, not recruiting

  A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients

  NCT06540391· Phase 1· Microbiotica Ltd· Source

• Recruiting

  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  NCT06216301· Phase 3· NovoCure GmbH· Source

• Recruiting

  VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

  NCT06264180· Phase 3· Replimune, Inc.· Source

• Recruiting

  A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

  NCT06515613· Phase 1· Context Therapeutics Inc.· Source

• Enrolling by invitation

  Prophylactic Prostatectomy for Prostate Cancer (PPPC)

  NCT06470685· Royal Marsden NHS Foundation Trust· Source

• Recruiting

  SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

  NCT05990192· Phase 2· Institute of Cancer Research, United Kingdom· Source

• Recruiting

  Breast Cancer Evolution During Neoadjuvant Systemic Therapy

  NCT06681064· Royal Marsden NHS Foundation Trust· Source

• Active, not recruiting

  A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

  NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT06158841· Phase 3· AbbVie· Source

• Recruiting

  Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)

  NCT06295731· Phase 2/3· Inhibrx Biosciences, Inc· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Recruiting

  A Study of MGC026 in Participants With Advanced Solid Tumors

  NCT06242470· Phase 1· MacroGenics· Source

• Recruiting

  Video Capsule Examination in Patients With Lynch Syndrome

  NCT06712095· Royal Marsden NHS Foundation Trust· Source

• Active, not recruiting

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

Showing 50 of 140.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer18 recruiting
• Prostate cancer11 recruiting
• Ovarian cancer10 recruiting
• Childhood cancers9 recruiting
• Colorectal cancer8 recruiting
• Melanoma8 recruiting
• Head and neck cancer6 recruiting
• Bladder cancer5 recruiting
• Multiple myeloma5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Follicular lymphoma4 recruiting
• Gastric and oesophageal cancer4 recruiting
• Pancreatic cancer4 recruiting
• Sarcoma4 recruiting
• Triple-negative breast cancer4 recruiting
• Endometrial cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Metastatic breast cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Cervical cancer2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Kidney cancer2 recruiting
• Chronic myeloid leukaemia1 recruiting
• Glioblastoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Thyroid cancer1 recruiting

Closed trials

• Withdrawn

  Molecular Analysis of Gastric and OEsophageal Cancers STudy

  NCT06702384· Royal Marsden NHS Foundation Trust· Source

• Terminated

  A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

  NCT05949632· Phase 1/2· Incyte Corporation· Source

• Withdrawn

  Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

  NCT05743270· Phase 2· Replimune, Inc.· Source

• Terminated

  Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

  NCT05814666· Phase 2· Flamingo Therapeutics NV· Source

• Completed

  A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom

  NCT05555979· AbbVie· Source

• Completed

  Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

  NCT05483933· Phase 1· Shattuck Labs, Inc.· Source

• Completed

  Randomised Study to Investigate the Effectiveness of Acupuncture for the Relief of Long COVID-19 Related Fatigue

  NCT05212688· Phase 2· Royal Marsden NHS Foundation Trust· Source

• Terminated

  A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

  NCT05389462· Phase 1· ADC Therapeutics S.A.· Source

• Terminated

  Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment

  NCT05435352· Ourotech, Inc.· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Incyte Corporation· Source

• Terminated

  A Study of SGN-ALPV in Advanced Solid Tumors

  NCT05229900· Phase 1· Seagen Inc.· Source

• Completed

  Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

  NCT05054725· Phase 2· Revolution Medicines, Inc.· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

  NCT05064059· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Changes to Function and Quality of Life and Patient Experience for Patients Undergoing Treatments for Recurrent Oropharyngeal Cancer

  NCT04952922· Royal Marsden NHS Foundation Trust· Source

• Completed

  A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

  NCT05014412· Phase 2· Pfizer· Source

• Terminated

  Study of INCA 0186 in Subjects With Advanced Solid Tumors

  NCT04989387· Phase 1· Incyte Corporation· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Gilead Sciences· Source

• Terminated

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

  NCT04949256· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Terminated

  (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

  NCT04862780· Phase 1· Blueprint Medicines Corporation· Source

• Completed

  Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC

  NCT04260126· Phase 2· PDS Biotechnology Corp.· Source

• Completed

  A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

  NCT04665843· Phase 2· Hoffmann-La Roche· Source

• Completed

  Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

  NCT04697628· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

  NCT04338399· Phase 3· Adlai Nortye Biopharma Co., Ltd.· Source

• Completed

  Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

  NCT04472429· Phase 3· Incyte Corporation· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

  NCT04199104· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR

  NCT04295577· Royal Marsden NHS Foundation Trust· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source

• Completed

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin

  NCT04021277· Phase 1· EXACT Therapeutics AS· Source

• Completed

  A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer

  NCT03981146· Phase 2· University of Birmingham· Source

• Terminated

  Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

  NCT03869190· Phase 1/2· Hoffmann-La Roche· Source

• Completed

  Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

  NCT03620643· Phase 2· Royal Marsden NHS Foundation Trust· Source

• Terminated

  Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

  NCT03645928· Phase 2· Iovance Biotherapeutics, Inc.· Source

• Completed

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

  NCT03648489· Phase 2· Imperial College London· Source

• Completed

  Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

  NCT03517449· Phase 3· Eisai Inc.· Source

• Terminated

  A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  NCT03452137· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma

  NCT03126019· Phase 2· Incyte Corporation· Source

• Completed

  Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT03391466· Phase 3· Kite, A Gilead Company· Source

• Completed

  ATRi Transition Rollover Study

  NCT03309150· Phase 1· Merck KGaA, Darmstadt, Germany· Source

• Completed

  Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

  NCT03260894· Phase 3· Incyte Corporation· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· Phase 3· Merck Sharp & Dohme LLC· Source

• Terminated

  A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT03215030· Phase 1/2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

  NCT03112174· Phase 3· Pharmacyclics LLC.· Source

• Completed

  Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

  NCT03040999· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

  NCT02730299· Phase 3· Gamida Cell ltd· Source

• Completed

  Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

  NCT02631447· Phase 2· Fondazione Melanoma Onlus· Source

Showing 50 of 57.

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer99 works · 19 trials
• Kidney cancer40 works · 6 trials
• Sarcoma37 works · 11 trials
• Ovarian cancer31 works · 24 trials
• Multiple myeloma22 works · 11 trials
• Metastatic breast cancer18 works · 10 trials
• Head and neck cancer16 works · 28 trials
• Neuroblastoma10 works · 1 trial
• Mesothelioma4 works · 1 trial